Edmolin.com

Informed Today Influential Tomorrow

Medicine

Enhancing drug delivery: Innovation for the future

Beth Tran, global business manager, CR Excipients, Colorcon, explains how innovations in controlled release systems, film coatings and functional excipients are driving the future of drug delivery.


Key Highlights:

  • Innovations in controlled release, film coatings, functional excipients and desiccant packaging are leading the way in addressing challenges in drug delivery.
  • Corelease technologies are engineered to simplify drug development and manufacturing processes, offering precise control over the release profile of APIs.
  • Colorcon systems allow for more efficient manufacturing processes, reducing the complexity and cost of bringing new drugs to market. 

The effectiveness of drug delivery systems is pivotal in improving patient outcomes, enhancing drug efficacy, and increasing adherence to treatment. The complexity of today’s medications has raised the stakes for pharmaceutical companies, making innovation in drug delivery a key focus. At its core, effective drug delivery ensures the right amount of active pharmaceutical ingredient (API) is delivered at the right time, to the right location in the body, while minimising side effects. 

Drug delivery encompasses a variety of methods, from the traditional oral tablets to more advanced systems. The challenge lies in optimising these systems to ensure that the API reaches its intended target in a controlled, reliable manner. As such, innovations in controlled release, film coatings, functional excipients and desiccant packaging are leading the way in addressing these challenges. 

The power of controlled release systems 

Controlled release technologies have reshaped how medications are delivered. By gradually releasing the API over an extended period, these systems provide a more consistent therapeutic effect, reducing the frequency of dosing. This not only improves the patient’s experience but also enhances treatment adherence—a critical factor in chronic conditions. 

At Colorcon, we have taken a leading role in advancing controlled release systems through our Corelease product line. Corelease technologies are engineered to simplify drug development and manufacturing processes, offering precise control over the release profile of APIs. This precision ensures that the drug maintains its efficacy over time while minimising adverse effects. 

With over 60 years of innovation, Colorcon’s dedication to controlled release technology helps pharmaceutical companies accelerate product development and improve the performance of their products. These systems allow for more efficient manufacturing processes, reducing the complexity and cost of bringing new drugs to market. 


Corelease technologies are engineered to simplify drug development and manufacturing processes, offering precise control over the release profile of APIs.”


The role of film coatings and excipients 

Film coatings play a vital role in pharmaceutical drug delivery. They protect the drug from environmental factors and can be customised to meet regulatory requirements. At Colorcon, we offer a range of film coatings that allow companies to design tablets with unique branding while enhancing their functionality. Our coatings are also formulated to provide a superior patient experience, with improved swallowability and taste masking, when needed. 

In addition to coatings, functional excipients are critical to ensuring the drug product is manufacturable and stable. Excipients support the API by improving solubility, enhancing bioavailability, and contributing to the overall effectiveness of the drug. Our excipients are backed by comprehensive application data, helping pharmaceutical companies streamline development and create robust, high-quality products. 

The future of drug delivery 

As the pharmaceutical landscape evolves, the demand for innovative drug delivery systems will only grow. Pharmaceutical companies must navigate regulatory hurdles, patient preferences, and the need for greater efficiency. At Colorcon, we are committed to helping our partners overcome these challenges by providing reliable, high-performance solutions that transform drug development and delivery. 

By focusing on controlled release technologies, advanced film coatings, functional excipients and desiccant packaging, we empower pharmaceutical companies to optimise their drug delivery strategies, drive manufacturing efficiency and ultimately improve patient outcomes. 

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *

Medicine

Aramex Scoop Sustainability AwardGlobal logistics giant Aramex has been awarded the Sustainability in Distribution award at the recent Distributing Pharmaceuticals UK award event at the Coventry Building Society Arena. The awards night recognised the very best in innovation and sustainability from those that are directly involved in the design, development or distribution of pharmaceuticals – a sector in which Aramex has a significant footprint. Despite being up against fierce competition within their selected category, the judges ruled that Aramex’s unwavering commitment to sustainability, environmental stewardship, and mitigating climate risks were what tipped the scales on the night. Citing a 42% reduction based on scope 1 & 2 and a 25% reduction on scope 3, dependent on supplier commitment, Aramex has since 2006 implemented a multifaceted climate change mitigation strategy with the sole aim of minimising its carbon footprint and improving its impact on the environment. This strategy involves investment into renewable energy projects, commitment to minimising waste and promoting recycling across its network, enhancing energy efficiency across its operations, with initiatives such as ISO 14001 certification, LEED certification for its facilities along with further energy efficiency projects to drive down usage. Reduced water consumption, route optimisation projects to reduce fuel consumption and emissions, and a commitment to gradually transitioning its fleet to electric and low-emission vehicles have also been put in place. Aramex has also implemented its Future Vehicle Program which explores innovative solutions such as autonomous vehicles and drone deliveries to enhance efficiency and reduce environmental impact in the years to come. Ronan Kitchin who heads up the Life Science and Healthcare division at Aramex UK commented: “We are delighted to have been recognised by Distributing Pharmaceuticals at their recent award event for our work in driving sustainability initiatives throughout our distribution services – a commitment which we have made significant strides towards over the past two decades. “With a legacy of championing sustainability, our environmental and climate change mitigation strategy looks to deliver tangible and positive changes in reducing emissions across the entire business – whether that be in our efforts to minimise waste or reducing fuel consumption. Ensuring our footprint is kept at a minimum where possible is at the top of our agenda and we couldn’t be prouder that this has been recognised by an independent panel of respected industry experts within the pharmaceutical industry – a sector within which we have a long and proud history serving. “Ultimately, it’s about doing the right thing. The world is undergoing a rate of change which is incomparable to anything humankind has ever faced before and therefore all need to play their part if the collective goal of defeating the worsening climate crisis is to be achieved. A huge thanks must therefore go out to all team members across the Aramex network who have each played a part in helping the company make such incredible inroads in its own sustainability goals.”